MariMed Inc. (MRMD) CCO Reports RSU Grant and Tax Share Withholding

Rhea-AI Filing Summary

MariMed Inc.'s Chief Commercial Officer Ryan Crandall reported stock-based compensation and related share movements dated December 15, 2025. He converted previously granted restricted stock units (RSUs) into 62,902 shares of common stock at a stated price of $0, and 18,462 shares were withheld to cover tax obligations, leaving him with 867,515 common shares held directly after the transactions.

On the same date, Crandall received a new grant of 1,000,000 RSUs, each convertible into one share of MariMed common stock. These RSUs were issued in lieu of a cash salary increase tied to his promotion to Chief Commercial Officer and will vest in four equal installments on June 15, 2026, December 15, 2026, June 15, 2027 and December 15, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crandall Ryan

(Last) (First) (Middle)

10 OCEANA WAY, 2ND FLOOR

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	12/15/2025		M		62,902	A	$0(1)	885,977	D
Common stock	12/15/2025		F		18,462(2)	D	$0.1071	867,515	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	12/15/2025		M			62,902	(3)	(3)	Common Stock, par value $.001 per share	62,902	$0	0	D
Restricted Stock Units (RSU)	(1)	12/15/2025		A		1,000,000		(4)	(4)	Common Stock, par value $.001 per share	1,000,000	$0	1,000,000	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.

3. These RSUs were granted on May 9, 2025; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

4. These RSUs will vest in four equal installments, on each of June 15, 2026, December 15, 2026, June 15, 2027 and December 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Remarks:

The RSUs granted on December 15, 2025 were issued in lieu of a cash salary increase in connection with the Reporting Person's promotion to Chief Commercial Officer.

	/s/ Ryan Crandall	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity transactions did MariMed (MRMD) report for its CCO on December 15, 2025?

Chief Commercial Officer Ryan Crandall converted RSUs into 62,902 shares of MariMed common stock at a stated price of $0, and 18,462 shares were disposed of to satisfy tax withholding obligations.

How many MariMed (MRMD) common shares does Ryan Crandall own after these transactions?

Following the reported transactions, Ryan Crandall beneficially owns 867,515 shares of MariMed common stock directly.

What new RSU grant did MariMed (MRMD) award to its Chief Commercial Officer?

On December 15, 2025, MariMed granted Ryan Crandall 1,000,000 restricted stock units (RSUs), each convertible into one share of MariMed common stock.

When will the 1,000,000 MariMed RSUs granted to the CCO vest?

The 1,000,000 RSUs will vest in four equal installments on June 15, 2026, December 15, 2026, June 15, 2027 and December 15, 2027.

Why did MariMed grant 1,000,000 RSUs to its Chief Commercial Officer?

The RSUs granted on December 15, 2025 were issued in lieu of a cash salary increase in connection with Ryan Crandall's promotion to Chief Commercial Officer.

Why were 18,462 MariMed (MRMD) shares withheld in this insider filing?

The 18,462 shares of common stock were withheld by MariMed to satisfy tax withholding obligations related to the vesting of RSUs.